Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Necitumumab - Eli Lilly and Company

Drug Profile

Necitumumab - Eli Lilly and Company

Alternative Names: IMC-11F8; LY 3012211; Portraza; Portrazza

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImClone Systems
  • Developer AstraZeneca; Eli Lilly and Company
  • Class Antineoplastics; Fab fragments; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 03 Jun 2022 Updated efficacy data from a phase I trial in Non-small cell lung cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 09 May 2022 Eli Lilly and AstraZeneca completes a phase-I clinical trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, France, Spain, Taiwan, Italy, South Korea (IV) (NCT02789345)
  • 26 Apr 2022 Necitumumab is still in phase-II trials for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in Spain (IV) (EdudraCT2018-003974-29) (NCT03944772)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top